Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Budget impact from clinical medication recommendations between drug classesRankDrug (class)Number issued and % of total medication recommendationsAnnual budget impactAnnual savings per patientMost saving (stop, lower, switch to less expensive drug)1Opioids40 (2.4%)€11,260€422Short or long acting beta receptor agonists37 (2.2%)€6,030€223Corticosteroids (including inhalations and topicals)34 (2.0%)€5,264€194Tamsulosin/solifenacin/mirabegron/dutasteride/tolterodine38 (2.2%)€4,624€175Short or long acting muscarine receptor antagonists19 (1.1%)€4,561€17Most costly (start, increase, switch to more expensive drug)1Erythropoietic growth factors4 (0.2%)€13,260-€492Sodium glucose transporter 2 inhibitors33 (2.0%)€11,771-€433Etanercept1 (0.1%)€7,990-€294Etravirine1 (0.1%)€4,373-€165Calcium and vitamin D formulations115 (6.8%)€4,318-€16Annual budget impact was based on 1,689 medication recommendations from 271 junior pharmacist-led medication reviews across hospital wards.

Source: Budget impact related to medication recommendations by drug class. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were selected for a medication review based on the following criteria:Polypharmacy (defined as the use of ≥ 5 medications for ≥ 3 months)And at least one of the following risk factors:At least two chronic conditionsImpaired renal function (eGFR < 50 ml/min/1.73 m.2)Cognitive impairmentIncreased risk of falling (≥ 1 fall in the previous 12 months)Evidence of decreased medication adherenceSuspected medication-related problem

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective

Study design awaiting verification · International Journal of Clinical Pharmacy · 2026

Original publication title

Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective

Toon Hectors; Thirza Kooijman; Marit van Barreveld; Marianne Kuijvenhoven; Patty Teeuwisse; Rik Olde Engberink

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Junior pharmacist-led medication reviews provide a modest cost-saving intervention from the hospital perspective, demonstrating savings across clinical populations with polypharmacy.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To assess the budget impact of medication reviews by supervised junior pharmacists across hospital wards, explore budget impact differences between drug classes, and identify patient predictors that potentially influence the budget impact.

Source: Aim

Abstract: What methods does the paper describe?

Data of medication reviews were collected over a 19-month period in patients with polypharmacy (≥ 5 medications) who had at least one additional risk factor. We developed a cost model over a one-year horizon, from the hospital perspective. Intervention costs were derived from measured labour time per medication review and salary of junior: and clinical pharmacists. Cost avoidance from potential preventable medication-related readmissions were based on admission time, admission costs and an estimate of preventable medication-related admissions (4.8%). Costs and savings from medication recommendations were aggregated using drug price per daily defined dose and its predicted days of therapy per year, and clustered by drug class.

Scenario analyses tested the robustness of medication recommendation savings to account for effectively implemented and additional monitoring recommendations. Patient predictors of budget impact related to medication recommendations were assessed using multivariable linear regression, including age, gender, eGFR, acute admission, medication count, comorbidity, expensive drugs, and ward type.

Source: Method

Abstract: Results

We collected 271 medication reviews, including 1,689 medication recommendations. Per-patient budget impact was negative for the intervention (€104 costs), but positive for medication recommendations (€46 savings), and preventable medication-related readmissions (€239 savings). Total estimated savings were €181 per patient, and €688,000 when upscaled hospital-wide. Opiates, beta receptor agonists, corticosteroids, urological drugs, and muscarine receptor antagonists generated 43% of medication recommendation savings. Erythropoietic growth factors, SGLT2 inhibitors, etanercept, etravirine, and calcium/vitamin D formulations generated 70% of medication recommendation costs. No significant associations were found between any of the included patient characteristics and budget impact related to medication recommendations.

Source: Results

Abstract: Conclusion

Junior pharmacist-led medication reviews provide a modest cost-saving intervention from the hospital perspective, demonstrating savings across clinical populations with polypharmacy.

Source: Conclusion
Authors’ abstract

Introduction

Pharmacist-led medication reviews are increasingly recognised for generating cost savings within the hospital. However, no cost-analysis has investigated the budget impact of junior pharmacists conducting medication reviews under supervision of clinical pharmacists, nor included recommendations to start-, increase-, or monitor medications.

Aim

To assess the budget impact of medication reviews by supervised junior pharmacists across hospital wards, explore budget impact differences between drug classes, and identify patient predictors that potentially influence the budget impact.

Method

Data of medication reviews were collected over a 19-month period in patients with polypharmacy (≥ 5 medications) who had at least one additional risk factor. We developed a cost model over a one-year horizon, from the hospital perspective. Intervention costs were derived from measured labour time per medication review and salary of junior: and clinical pharmacists. Cost avoidance from potential preventable medication-related readmissions were based on admission time, admission costs and an estimate of preventable medication-related admissions (4.8%). Costs and savings from medication recommendations were aggregated using drug price per daily defined dose and its predicted days of therapy per year, and clustered by drug class.

Scenario analyses tested the robustness of medication recommendation savings to account for effectively implemented and additional monitoring recommendations. Patient predictors of budget impact related to medication recommendations were assessed using multivariable linear regression, including age, gender, eGFR, acute admission, medication count, comorbidity, expensive drugs, and ward type.

Results

We collected 271 medication reviews, including 1,689 medication recommendations. Per-patient budget impact was negative for the intervention (€104 costs), but positive for medication recommendations (€46 savings), and preventable medication-related readmissions (€239 savings). Total estimated savings were €181 per patient, and €688,000 when upscaled hospital-wide. Opiates, beta receptor agonists, corticosteroids, urological drugs, and muscarine receptor antagonists generated 43% of medication recommendation savings. Erythropoietic growth factors, SGLT2 inhibitors, etanercept, etravirine, and calcium/vitamin D formulations generated 70% of medication recommendation costs. No significant associations were found between any of the included patient characteristics and budget impact related to medication recommendations.

Conclusion

Junior pharmacist-led medication reviews provide a modest cost-saving intervention from the hospital perspective, demonstrating savings across clinical populations with polypharmacy.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s11096-026-02190-4.

Publication and source details

Original title: Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective

Toon Hectors; Thirza Kooijman; Marit van Barreveld; Marianne Kuijvenhoven; Patty Teeuwisse; Rik Olde Engberink

International Journal of Clinical Pharmacy · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:06:33.921956+00:00

DOI: 10.1007/s11096-026-02190-4 · PMC13569556